Simultaneous quantitation of befotertinib (D-0316) and its metabolite D-0865 in human plasma by LC-MS/MS method

A sensitive and reliable method was developed to determine befotertinib (D-0316) and its metabolite D-0865 from human plasma by LC-MS/MS. The samples were prepared by simple protein precipitation and 2 mu L of the supernatant were chromatographed on a C18 analytical column (ACE Excel 2 Super C-18, 50 x 2.1 mm). Elution was performed with mobile phase A (10 mM ammonium acetate in water containing 1 % formic acid) and mobile phase B (acetonitrile containing 1 % formic acid) under a gradient program in a total run time of 4 min. Triple Quadruple 5500 equipped with Turbo Ion Spray source and multiple reaction monitoring (MRM) were used for the analysis detection. The transitions were m/z 568.3 -> 72.1 m/z (befotertinib), m/z 554.2 -> 497.2 (D-0865), and m/z 455.2 -> 164.9 (verapamil, internal standard). According to the Chinese Pharmacopeia Commission and ICH Harmonised Guideline for Bioanalytical Method Validation, this method was validated within the spectrum of its accuracy, precision, selectivity, linearity, recovery, matrix effect, and stability. This LC-MS/MS method was successfully applied for the quantitation of befotertinib and its metabolite D-0865 in human plasma during the pharmacokinetics study of befotertinib in non-small cell lung cancer (NSCLC) patients.

Automated summary

A sensitive and reliable LC-MS/MS method was developed for the determination of befotertinib and its metabolite D-0865 in human plasma. The method was validated according to the Chinese Pharmacopeia Commission and ICH Harmonised Guideline for Bioanalytical Method Validation. It was successfully applied for the quantitation of befotertinib and D-0865 during the pharmacokinetics study of befotertinib in NSCLC patients.